[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546551":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":43,"locations":50,"responsibleParty":71,"collaborators":74,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":19,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":19,"enrollmentInfo":90,"targetDuration":19,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":52,"whyStopped":19,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Western University, Canada","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Virtual Weight Management Program","EXPERIMENTAL","A maximum tolerated dose of semaglutide (Ozempic\u002FWegovy) will be administered once weekly subcutaneously, up to a dose of 2.0 mg. Participants will also receive nutritional and movement advice, as well as virtual coaching once every 4 weeks for 6 months.",[13,14],"Drug: Semaglutide","Behavioral: Virtual Weight Management Coaching",{"label":16,"type":17,"description":18,"interventionNames":19},"Usual Care","NO_INTERVENTION","Usual care participants will continue to receive the typical standard of kidney and diabetes care. They will not receive any study medication or coaching.",null,[21,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Semaglutide","Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.",[9],[27,28,29],"GLP-1RA","Ozempic","Wegovy",{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":19},"BEHAVIORAL","Virtual Weight Management Coaching","Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.",[9],[36,40],{"name":37,"affiliation":38,"role":39},"Kristin K Clemens, MD, MSc","St. Joseph's Health Care London","PRINCIPAL_INVESTIGATOR",{"name":41,"affiliation":42,"role":39},"Louise Moist, MD, MSc","London Health Sciences Centre",[44],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Heather LaPier, BSc","CONTACT","519-646-6100","65373","heather.lapier@sjhc.london.on.ca",[51],{"facility":42,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","London","Ontario","N6A 5A5","Canada","CA",{"type":59,"coordinates":60},"Point",[61,62],-81.23304,42.98339,{"lat":62,"lon":61},[65,66,68],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},{"name":67,"role":39,"phone":19,"phoneExt":19,"email":19},"Louise Moist, MD",{"name":69,"role":70,"phone":19,"phoneExt":19,"email":19},"Michael Chiu, MD","SUB_INVESTIGATOR",{"type":39,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Kristin Clemens","Associate Professor",[75,77,79],{"name":76,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"name":78,"class":6},"Queen Elizabeth II Health Sciences Centre",{"name":80,"class":6},"Unity Health Toronto","100546551","phase-4-obesity-management-for-kidney-transplantation-ok-transplant-2-100546551",false,"NCT06396416","Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2","Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* BMI; 35 kg\u002Fm\\^2\n* 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis\n\nExclusion Criteria:\n\n* Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity)\n* Type 1 diabetes\n* No access to semaglutide via drug coverage\n* Pregnant, breastfeeding or planning to become pregnant\n* Currently in a GLP-1RA or GLP-1RA\u002FGIP study or planning to be in one","ALL","18 Years",{"count":91,"type":92},60,"ESTIMATED","INTERVENTIONAL",[95],"PHASE4","OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.\n\nWe will randomize participants with obesity, high-risk CKD\u002Fdialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.",[98,99],"Obesity","Chronic Kidney Disease",[101,102,27,103,104,105],"Weight Management","Transplant","Pilot Study","Registries","Pragmatic","2026-06-24",{"date":108,"type":109},"2026-06-29","ACTUAL",{"date":111,"type":109},"2024-09-26",{"date":113,"type":92},"2026-12",{"name":5,"class":6},1]